Department of Pharmaceutical Sciences, The University of Connecticut, Storrs, CT 06269, USA.
Protein Sci. 2012 Jan;21(1):13-25. doi: 10.1002/pro.757. Epub 2011 Nov 22.
Signal peptidase I (SPase I) is critical for the release of translocated preproteins from the membrane as they are transported from a cytoplasmic site of synthesis to extracytoplasmic locations. These proteins are synthesized with an amino-terminal extension, the signal sequence, which directs the preprotein to the Sec- or Tat-translocation pathway. Recent evidence indicates that the SPase I cleaves preproteins as they emerge from either pathway, though the steps involved are unclear. Now that the structure of many translocation pathway components has been elucidated, it is critical to determine how these components work in concert to support protein translocation and cleavage. Molecular modeling and NMR studies have provided insight on how the preprotein docks on SPase I in preparation for cleavage. This is a key area for future work since SPase I enzymes in a variety of species have now been identified and the inhibition of these enzymes by antibiotics is being pursued. The eubacterial SPase I is essential for cell viability and belongs to a unique group of serine endoproteases which utilize a Ser-Lys catalytic dyad instead of the prototypical Ser-His-Asp triad used by eukaryotes. As such, SPase I is a desirable antimicrobial target. Advances in our understanding of how the preprotein interfaces with SPase I during the final stages of translocation will facilitate future development of inhibitors that display a high efficacy against SPase I function.
信号肽酶 I(SPase I)对于跨膜易位前体蛋白的释放至关重要,因为它们在从细胞质合成部位运输到细胞外位置的过程中被转运。这些蛋白质在氨基末端有一个延伸,即信号序列,它将前体蛋白导向 Sec 或 Tat 易位途径。最近的证据表明,SPase I 在易位途径中切割前体蛋白,尽管涉及的步骤尚不清楚。现在已经阐明了许多易位途径成分的结构,因此确定这些成分如何协同作用以支持蛋白质易位和切割是至关重要的。分子建模和 NMR 研究提供了关于前体蛋白在切割前如何与 SPase I 对接的见解。这是未来工作的一个关键领域,因为现在已经鉴定出了各种物种的 SPase I 酶,并且正在通过抗生素抑制这些酶。原核生物的 SPase I 对细胞活力至关重要,属于一组独特的丝氨酸内肽酶,它们利用 Ser-Lys 催化二联体,而不是真核生物使用的典型 Ser-His-Asp 三联体。因此,SPase I 是一种理想的抗菌靶标。在易位的最后阶段,前体蛋白与 SPase I 相互作用的理解的进展将有助于未来开发针对 SPase I 功能显示出高疗效的抑制剂。